A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer

Cancer- United States

doi 10.1002/cncr.24870

Full Text

Abstract

Available in

Date

Authors

Publisher

Wiley

Related search

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

KEYNOTE-045: Randomized Phase 3 Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Metastatic Urothelial Cancer.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

A Randomized Phase II Study Evaluating Different Maintenance Schedules of Nab-Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer: Final Results of the IBCSG 42-12/Big 2-12 SNAP Trial

Annals of Oncology
MedicineOncologyHematology
2018English

2′-Behenoyl-Paclitaxel Conjugate Containing Lipid Nanoparticles for the Treatment of Metastatic Breast Cancer

Cancer Letters
Cancer ResearchOncology
2013English

Evaluation of the 48 Hour, 72 Hour and 96 Hour Readings of Tuberculin Test for the Screening of Tuberculosis in Cattle

African Journal of Clinical and Experimental Microbiology
2005English

A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients With Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients With Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2005English

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
1999English

Design of RESILIENCE: A Phase 3 Trial Comparing Capecitabine in Combination With Sorafenib or Placebo for Treatment of Locally Advanced or Metastatic HER2-negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy